Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology
The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Histone deacetylases (HDACs) are expressed at increased levels in cells of various malignancies, and the use of HDAC inhibitors has improved outcomes in patients with haematological malignancies (T-cell lymphomas and multiple myeloma). However, they are not as effective in solid tumours. Five agents are currently approved under various jurisdictions, namely belinostat, chidamide, panobinostat, romidepsin and vorinostat. These agents are associated with a range of class-related and agent-specific serious and/or severe adverse effects, notably myelosuppression, diarrhoea and various cardiac effects. Among the cardiac effects are ST-T segment abnormalities and QTc interval prolongation of the electrocardiogram, isolated cases of atrial fibrillation and, in rare instances, ventricular tachyarrhythmias. In order to improve the safety profile of this class of drugs as well as their efficacy in indications already approved and to further widen their indications, a large number of newer HDAC inhibitors with varying degrees of HDAC isoform selectivity have been synthesised and are currently under clinical development. Preliminary evidence from early studies suggests that they may be effective in non-haematological cancers as well when used in combination with other therapeutic modalities, but that they too appear to be associated with the above class-related adverse effects. As the database accumulates, the safety, efficacy and risk/benefit of the newer agents and their indications wi…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“KDAC inhibitors often exhibit sub-optimal efficacy in the clinic (especially when administered to patients with solid tumors) as well as side effects such as blood thinning, cardiac abnormalities, and nausea/vomiting [28].”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [28]
In the citing paper
“There is increasing evidence that KDAC inhibitors work best in combination with other therapies [28–30]”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [28]
In the citing paper
“HDAC3 was found to be required for genome maintenance and DNA replication in hematopoietic cells (27, 28); therefore, HDAC3 inhibition is suspected to be responsible for bone marrow toxicity seen with nonselective HDAC inhibitors (29).”
From TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11 -Mutant Tumors to Anti–PD-1 Immunotherapy (2025) · cites this paper as [29]
Citations
Cites
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
Gottlicher, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.6969 · Cited by 1,887
New and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404
Histone Deacetylase Inhibitors as Anticancer Drugs
Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071414 · Cited by 1,206
Suraweera, A., O’Byrne, K. J., & Richard, D. J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00092 · Cited by 669
Histone deacetylases, transcriptional control, and cancer
Cress, W. D., & Seto, E. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200007)184:1<1::aid-jcp1>3.0.co;2-7 · Cited by 621
Molecular and Therapeutic Potential and Toxicity of Valproic Acid
Chateauvieux, S., Morceau, F., Dicato, M., & Diederich, M. (2010) · Journal of Biomedicine and Biotechnology · doi:10.1155/2010/479364 · Cited by 512
Targeted Cancer Therapy: Giving Histone Deacetylase Inhibitors All They Need To Succeed
Gryder, B. E., Sodji, Q. H., & Oyelere, A. K. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.3 · Cited by 404
Clinical Toxicities of Histone Deacetylase Inhibitors
Subramanian, S., Bates, S. E., Wright, J. J., Espinoza-Delgado, I., & Piekarz, R. L. (2010) · Pharmaceuticals · doi:10.3390/ph3092751 · Cited by 386
Shi, Y., Dong, M., Hong, X., Zhang, W., Feng, J., Zhu, J., Yu, L., Ke, X., Huang, H., Shen, Z., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv237 · Cited by 385
Histone acetylation and disease
Timmermann, S., Lehrmann, H., Polesskaya, A., & Harel-Bellan, A. (2001) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000896 · Cited by 341
Cited by
Items 101–200 of 202
Design, synthesis, and biological evaluation of indazole-based histone deacetylase 6 inhibitors
Ali, K. H., Gupta, S., Oh, Y. J., Hossain, M. M., Kim, J. H., Park, S. Y., & Seo, Y. H. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117785 · Cited by 7
A novel selective histone deacetylase I inhibitor CC-4a activates latent HIV-1 through NF-κB pathway
Lu, W., Yang, C., Xu, X., Chen, C., Hou, X., Fang, H., & Liu, S. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118427 · Cited by 7
Liva, S. G., Chen, M., Mortazavi, A., Walker, A., Wang, J., Dittmar, K. M., Hofmeister, C. C., Coss, C. C., & Phelps, M. A. (2021) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-021-00722-z · Cited by 8
Menezes, A., Julião, G., Mariath, F., Ferreira, A. L., Oliveira-Nunes, M. C., Gallucci, L., Evaristo, J. A. M., Nogueira, F. C. S., Pereira, D. D. A., & Carneiro, K. (2024) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2024.100722 · Cited by 8
“To date the FDA-approved iHDACs for Peripheral T-cell lymphoma are Belinostat and Romidepsin, for Multiple Myeloma Panobinostat and for Cutaneous T-cell lymphoma Romidepsin and Vorinostat (SAHA) (43, 47). iHDACs have also been extensively studied using in vitro assays and different GBM cells.”
BackgroundTherapeutic indications for HDAC6 inhibitors in the peripheral and central nervous disorders
van Eyll, J. M., Prior, R. C., Célanire, S., Bosch, L. V. D., & Rombouts, F. J. R. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2404571 · Cited by 8
“The poor selectivity of this class versus the HDAC isozymes is linked to various clinical toxicities including myelosuppression and cardiac, gastrointestinal, and hepatic effects [164,165].”
Ruan, Y., Guan, L., Wang, Y., Geng, Y., Wang, X., Niu, M., Li, Y., Xu, C., & Xu, Z. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s479113 · Cited by 7
“35,36 So the development of specific HDAC2 inhibitors is particularly important.”
Improved Pharmacokinetic Profiles of HDAC6 Inhibitors via Cap Group Modifications
Olaoye, O. O., Erdogan, F., Gracia-Hernandez, M., Garcha, H. K., Sedighi, A., Ashraf, Q. F., Nawar, N., Geletu, M., Seo, H., Abdallah, D. I., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00479 · Cited by 8
Epigenetic regulation in coronary artery disease: from mechanisms to emerging therapies
Gao, R., Liu, M., Yang, H., Shen, Y., & Xia, N. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1548355 · Cited by 7
Targeted Drugs for Cancer Therapy: Small Molecules and Monoclonal Antibodies
Baldo, B. A., & Pham, N. H. (2020) · Springer eBooks · doi:10.1007/978-3-030-51740-3_14 · Cited by 6
Pradel, L. S., Ho, Y.-L., Gohlke, H., & Kassack, M. U. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158455 · Cited by 6
“…α -lipoic acid [19,20], an approved drug for the treatment of diabetic polyneuropathy, a food supplement, and with reported pleiotropic anticancer effects [23–26]. α -lipoic acid is rather non-toxic with a very low side-effect profile, particularly compared to other HDAC inhibitors [41].”
Garcha, H. K., Nawar, N., Sorger, H., Erdogan, F., Aung, M. M. K., Sedighi, A., Manaswiyoungkul, P., Seo, H., Schönefeldt, S., Pölöske, D., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15111321 · Cited by 7
“Despite being in the same classical HDAC family, the individual HDAC proteins vary substantially in their function, and the inhibition of more than one family member may lead to undesirable effects [43].”
BackgroundSynergistic strategies: histone deacetylase inhibitors and platinum-based drugs in cancer therapy
Shirbhate, E., Singh, V. P., Kore, R., Koch, B., Veerasamy, R., Tiwari, A. K., & Rajak, H. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2458156 · Cited by 8
“However, the molecules limit their clinical utility in oncology investigations, owing to toxicities like thrombocytopenia, neutropenia, cardiovascular effects, gastrointestinal abnormalities, and weariness [12].”
Ashraf, R., Adel, M., Serya, R. A. T., Ibrahim, E., Haffez, H., Soror, S. H. A., & Abouzid, K. A. M. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108514 · Cited by 5
Risk of infection associated with new therapies for lymphoproliferative syndromes
Arcos, I. L., & Ruíz-Camps, I. (2020) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2019.07.006 · Cited by 5
Bieszczad, B., Garbicz, D., Świtalska, M., Dudek, M. K., Warszycki, D., Wietrzyk, J., Grzesiuk, E., & Mieczkowski, A. (2021) · Preprints.org · doi:10.20944/preprints202105.0251.v1 · Cited by 5
“However, it should be taken under consideration that HDAC inhibitors can cause a number of side effects [81] and their potential use and success in cancer therapy is highly dependent on difficulties to achieve selectivity, decrease toxicity and reduce the adverse effects [82,83].”
BackgroundNikolakis, D., Yim, A. Y. F. L., Overberg, K. L., Ghiboub, M., Wildenberg, M. E., de Jonge, W. J., Lartey, D. A., Rieder, F., D’Haens, G., van de Sande, M. G. H., et al. (2025) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjaf137 · Cited by 6
Zhang, Q., Geng, Y., 陈海涛, Ni, J., Guan, L., Zhai, D., Wang, Y., Xu, S., Niu, M., Zheng, L., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02435 · Cited by 4
Schliehe‐Diecks, J., Tu, J., Stachura, P., Schaal, K., Kemkes, M., Vasileiou, E., Rüchel, N., Brandes, D., Vogt, M., Lenz, T., et al. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08541-3 · Cited by 4
“This lack of speci fi city leads to a range of adverse effects, including cardiac toxicity and severe gastrointestinal disturbances, some of which can be life-threatening [10 – 12].”
Spadotto, V., Ripamonti, C., Ghiroldi, A., Galbiati, E., Pozzi, P., Noberini, R., Bonaldi, T., Steinkühler, C., & Fossati, G. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1546939 · Cited by 6
“However, the therapeutic index of these inhibitors is narrow, and dose-limiting toxicities, such as thrombocytopenia, are observed in the clinic (14, 15).”
Yin, T., Liu, Y., Li, C., Feng, X., Lin, Y., & Qu, Z. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1563797 · Cited by 5
“Previous studies have shown that the combination of HDAC inhibitors with other drugs for cancer treatment has more signi fi cant advantages than single treatment, providing a new idea for cancer treatment (Shah, 2019).”
Vystorop, I. V., Shilov, G. V., Chernyak, A. V., Klimanova, E. N., Sashenkova, T. E., Klochkov, S. G., Неганова, М. Е., Aleksandrova, Y. R., Allayarova, U. Y., & Mishchenko, D. V. (2021) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162021030171 · Cited by 4
Furze, R. C., Molnár, M. J., Parr, N. J., Ahmad, F. F., Henry, Y., Howe, D. C., Singh, R. P., Toal, M., Bassil, A. K., Bernard, S. G., et al. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15428 · Cited by 3
“These molecules have restricted clinical utility beyond oncology studies due to toxicities including thrombocytopaenia, neutropaenia, cardiovascular effects, gastrointestinal disturbances and fatigue.(11) However, there is also wider interest in areas such as heart disease,(12) diabetes,(13) neurological indications,(…”
BackgroundAndré, A., Dias, J., Aguiar, S. I., Leonardo, A., Nogueira, S., Amaral, J. D., Fernandes, C., Gano, L., Correia, J. D. G., Cavaco, M. C., et al. (2023) · Frontiers in Veterinary Science · doi:10.3389/fvets.2023.1236136 · Cited by 5
Chowdhury, A., Marin, A., Weber, D. J., & Andrianov, A. K. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111834 · Cited by 4
Safety of Novel Targeted Therapies in Oncology
Shah, R. R., & Curigliano, G. (2019) · Drug Safety · doi:10.1007/s40264-018-0770-z · Cited by 4
Self-citationXiao, S., Xu, X.-Z., Liao, M., Song, D., Tang, J., & Zhou, C.-F. (2025) · World Journal of Clinical Oncology · doi:10.5306/wjco.v16.i8.108768 · Cited by 3
Peng, J., Yang, J., Antonopoulou, G., Fang, R., Adhikari, B., Vogt, M., Wolf, E., Sun, C., Du, S., Godfrey, L., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-69013-y · Cited by 4
“However, successful clinical development of HDAC inhibitors has been limited by low on-target speci fi city and treatment-associated toxicities, e.g., cardiotoxicity and myelosuppression 51,52 .”
Shirazi, M. M. A., & Sadat, S. M. (2026) · Virus Research · doi:10.1016/j.virusres.2026.199750 · Cited by 4
Advances of HDAC dual inhibitors in breast cancer treatment
Wu, C., Wu, J., Li, N., Liang, M., Feng, R., Kong, X., Zhou, H., & Nie, J. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118372 · Cited by 4
Gao, Y., Zheng, K., Kang, M., Xu, J., Ning, Y., Hu, W., Li, K., Kang, Y., & Xu, C. (2023) · Human Cell · doi:10.1007/s13577-023-00966-8 · Cited by 3
Fu, T., Chen, Y., Lou, L., Li, Z., Shi, W., Zhang, X., & Yang, J. (2024) · The Egyptian Heart Journal · doi:10.1186/s43044-023-00434-6 · Cited by 3
“HDACs are expressed at increased levels in various malignant tumors and are considered one of the prominent targets for anticancer therapy [43].”
BackgroundXia, W.-F., Zheng, X.-L., Liu, W., Huang, Y., Wen, C., Zhou, H., Wu, Q., & Wu, L. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00760-0 · Cited by 4
“Its activity depends not only on the cancer types, but also on the downstream molecules and its dose [25].”
Nishida, S., Konno, T., Kohno, T., Ohyanagi, M., Nakano, M., Ohwada, K., Obata, K., Kakuki, T., Kakiuchi, A., Kurose, M., et al. (2024) · Tissue Barriers · doi:10.1080/21688370.2024.2437215 · Cited by 3
“19,20 Trichostatin A (TSA) is a strong and specific inhibitor of class I and II HDACs that has antitumor effects in various cancers, including those of the head and neck.”
Morales-Herrejón, G., García-Vázquez, J. B., Fernández–Pomares, C., Bakalara, N., Correa‐Basurto, J., & Mendoza-Figueroa, H. L. (2025) · Pharmaceuticals · doi:10.3390/ph18030351 · Cited by 3
“However, most of these drugs contain a hydroxamic acid fragment, leading to toxic effects due to binding to other zinc-dependent enzymes and poor pharmacokinetics, causing a numerous side effects such as fatigue, nausea, and thrombocytopenia [3–6].”
Interplay Between the Epigenome, the Microenvironment, and the Immune System in Neuroblastoma
Andrade-Pérez, V., & Raynal, N. J. ‐. (2025) · Cancers · doi:10.3390/cancers17111812 · Cited by 3
“Since broad-spectrum HDAC inhibitors lack selectivity, their clinical use is associated with adverse effects like nausea, fatigue, diarrhea, anorexia, myelosuppression, and cardiac toxicity [85].”
Off-target binding of the histone deacetylase inhibitor vorinostat to carbonic anhydrase II and IX
Gulkis, M., Hodgkinson, J. T., Sèle, C., Knecht, W., McKENNA, R. V., & Fisher, S. Z. (2025) · Acta Crystallographica Section F Structural Biology Communications · doi:10.1107/s2053230x25007447 · Cited by 3
Rahim, N. A. H. A., Mahmood, A. A. R., Tahtamouni, L. H., Bawadi, R., Almasri, A. Y., Hamad, M. A., Hussein, N. E., Yasin, S. R., & Saleh, A. M. (2025) · Chemistry & Biodiversity · doi:10.1002/cbdv.202501492 · Cited by 2
“HDACis have a wide spectrum of adverse effects, from headaches to serious conditions like myelosuppression, much like any other medication [7].”
Molecular basis of the activity of a photoswitchable histone deacetylase inhibitor
Queizán, M., Teijeira, M., & Hermida‐Ramón, J. M. (2025) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2025.128488 · Cited by 2
Zhao, L., Liu, Y., Li, P., Zhao, A., Zhang, H., Pang, C., Chen, S., Xue, B., Li, Z., Qian, W., et al. (2025) · Immunity & Inflammation · doi:10.1007/s44466-025-00010-4 · Cited by 2
“Fourth, the relatively short median follow-up (6.13 months post salvage) precludes assessment of long-term survival or delayed toxicity, particularly given the known hematologic and cardiac risks associated with HDAC inhibitors [28, 29].”
InfluentialHistones deacetylases in the epidermis: structure, functions and therapeutic implications
Van, C. N., & Lamartine, J. (2025) · Frontiers in Epigenetics and Epigenomics · doi:10.3389/freae.2025.1711733 · Cited by 3
“In addition, various cardiac abnormalities including ST-T segment abnormalities and QTc interval prolongation of the electrocardiogram also have been observed (Shah, 2019).”
Recommended Tool Compounds: Isoform- and Class-Specific Histone Deacetylase Inhibitors
Schäker‐Hübner, L., & Hansen, F. K. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00619 · Cited by 5
Histone deacetylase enzyme activity is not the universal anticancer target of HDAC inhibitors
Rai, C., Ruan, H., Li, X., Li, W., Jeong, H.-H., Song, C., Liu, P., Chang, Y., Fang, H., Udhaya Kumar., S., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02698-1 · Cited by 3
“8,9,11 De fi ning the molecular basis of their anticancer activity is key to overcoming these challenges and enabling next-generation therapeutics.”
Zhong, R., Qiu, C., Chan, S., Wang, Y., Liu, K., Yi, X., Zhang, H., & Zou, B. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.111817 · Cited by 2
Chen, C., Ma, X., Wan, Y., Zhong, Y., Hou, X., Fang, H., & Liang, T. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108562 · Cited by 2
Histone deacetylase inhibitors in medical therapeutics
Chun, P. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823928-5.00029-3 · Cited by 2
Characterizing HDAC Pathway Copy Number Variation in Pan-Cancer
Yang, S., Xie, S., Shi, X., Su, D., He, B., Xu, Y. Y., & Liu, Z. (2022) · Pathology & Oncology Research · doi:10.3389/pore.2022.1610288 · Cited by 2
“Despite the fact that five HDACis, including belinostat, chidamide, panobinostat, romidepsin, and vorinostat, have been approved for clinical treatment, they are still associated with many adverse reactions, especially bone marrow suppression, diarrhea and various adverse cardiac reactions [6].”
BackgroundResistance to Histone Deacetylase Inhibitors in the Treatment of Lymphoma
Flower, A. M., & Abla, O. (2019) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-030-24424-8_5 · Cited by 2
Giancotti, G., French, R., Hayward, O. A., Lee, K. Y., Robinson, T., da Silva, A. M. R., Varnava, A., MacFarlane, M., Clarkson, R. W. E., Westwell, A. D., et al. (2025) · Academia oncology. · doi:10.20935/acadonco7680 · Cited by 4
“However, such nonspecific inhibitors have shown toxicity in phase I trials [14, 15].”
Ali, K. H., Sharma, C., Oh, Y. J., Yu, J., Kim, S., Lee, H.-J., & Seo, Y. H. (2025) · Molecular Pharmacology · doi:10.1016/j.molpha.2025.100062 · Cited by 2
Lv, C., Zhao, Y., Luo, L., Ye, C., Rao, C., Feng, B., Yu, W., Xiao, X., Wang, C., & Huang, W. (2025) · Scientific Reports · doi:10.1038/s41598-025-23887-y · Cited by 1
“However, clinical trials of these agents have demonstrated unsatisfactory safety and efficacy in cancer treatment 21 .”
Epigenetics modulation of drug resistance pathways in advanced lung cancer
Sayed, U., Suleman, A. D., Al-Hasnaawei, S., Renuka Jyothi, S., Nayak, P. P., Bhatt, A., Chauhan, A. S., & Singla, S. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.112278 · Cited by 1
Leveraging multi-organ models for drug combination therapy safety
Mieville, V., Gubała, J., Han, S., Ota, M., Andreu‐Carbó, M., Molica, F., Benamran, D. A., Kwak, B. R., Valério, M., & Nowak-Sliwinska, P. M. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118847 · Cited by 2
Garcia-Franco, P. M., Falcó-Martí, F. J., Jeblaoui, H., del Rio, M. A., Ortega-Alarcón, D., Vega, S., Galano-Frutos, J. J., Abián, O., & Velázquez‐Campoy, A. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.149851 · Cited by 1
Liang, Y., Du, C., Wang, L., Liu, W., Jiang, Y., & Wang, Y. (2026) · Medicine · doi:10.1097/md.0000000000047449 · Cited by 1
“[45] This study also identified febrile neutropenia as a common adverse event.”
Liu, J.-Y., Quan, Y., Wang, Y.-L., Nie, W.-Z., Cui, C.-M., Zhao, B., Cui, N.-N., Lian, Q.-B., Li, G., & Shen, Q. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118697 · Cited by 2
Epigenetic regulation in cancer metastasis
Sun, Z., Wu, Y., Zong, X., Liu, H., Sun, X., Wang, S., & Liu, J. (2026) · Discover Oncology · doi:10.1007/s12672-026-04903-7 · Cited by 1
“Many drugs targeting epigenetic molecules exhibit pan-inhibitory effects, leading to significant off-target effects [164].”
Epigenetic remodeling in sarcoma promotes T-cell infiltration via modulation of the Hippo pathway
Santos, M. C. D. L., Chen, Y., Zárate, A. G. D., Sorteberg, A. L., Zhao, H., Vázquez-Cabrera, G., bigdeli, N., Kolbeinsdóttir, S., Mannion, A. J., Baldran-Groves, L., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-014601 · Cited by 3
Yu, B., Wang, N., Lou, G., Wu, L., Wang, Y., Yin, S., Lu, Y., Xu, J., Wang, Z., Chen, X., et al. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109877 · Cited by 2
Epigenetic reprogramming of hepatic antigen presenting cells in chronic liver disease
Ángel‐Gomis, E., Juanola, O., Caparrós, E., & Francés, R. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1783588 · Cited by 1
Use of Cell Biology to Identify Cellular Targets in Drug Development Process against Leishmania Sp.
Miranda, G. D. S. D. S. E., Godinho, J. L. P., de Macedo-Silva, S. T., Verçoza, B. R. F., da Rocha, A. A., Sodré, M. B. P. D. A., Ramos, V. F. D. S., & Rodrigues, J. C. F. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.101662 · Cited by 1
Oncology: Way Forward from Clinical and Molecular Diagnosis to Treatment
Srivastava, S., & Pandey, A. (2023) · Springer eBooks · doi:10.1007/978-981-99-1529-3_1 · Cited by 2
Das, D., Banerjee, R., Bandyopadhyay, M., & Nag, A. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2281635 · Cited by 2
“Similarly, fatigue, gastrointestinal symptoms, cardiac toxicity, and neuropathy were also commonly reported for synthetic HDAC inhibitors (Pal et al., 2023; Shah, 2019).”
Expanding the HDAC druggable landscape beyond enzymatic activityPreprint
Olivet, J., Choi, S. G., Sierra, S., O’Grady, T. M., Revenga, M. D. L. F., Laval, F., Botchkarev, V. V., Gorgulla, C., Coote, P. W., Blavier, J., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.07.519454 · Cited by 1
Bauer, N., Balourdas, D.-I., Schneider, J. R., Zhang, X., Berger, L. M., Berger, B., Klopp, N. A., Siveke, J. T., Knapp, S., & Joerger, A. C. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.18.547334 · Cited by 1
“As an HDAC inhibiting moiety, most dual BET/HDAC inhibitors are based on suberoyl anilide hydroxamic acid (SAHA), a pan-HDAC inhibitor with a relatively short metabolic half-life of 2 h [24].”
BackgroundSíndrome de Sézary. Tratamiento
Alonso, B., Arias, M., & Abeldaño, A. M. (2020) · Dermatología Argentina · doi:10.47196/da.v26i2.2074
The clinical landscape of HDAC inhibitors
Ganesan, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823928-5.00036-0
Evaluation of Small-Molecule HDAC Inhibitors Through In Vitro and In Cellulo Approaches
Nawar, N., Garcha, H. K., Sedighi, A., de Araujo, E. D., & Gunning, P. T. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2788-4_11
Data from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
Ramos, L., Truong, S., Zhai, B., Joshi, J., Ghaidi, F., Lizardo, M. M., Shyp, T., Kung, S. H. Y., Rezakhanlou, A. M., Oo, H. Z., et al. (2023) · doi:10.1158/1078-0432.c.6717743.v2 · Cited by 1
Wu, L., Xia, W., Zheng, X., Liu, W., Huang, Y., Wen, C., Wu, Q., & Zhou, H. (2023) · Research Square · doi:10.21203/rs.3.rs-3719026/v1
Targeting reader domains of the epigenetic code
Bauer, N. (2024) · Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) · doi:10.21248/gups.83192
The Discovery of Small Molecule Inhibitors of cFLIP that Sensitise Tumour Cells to TRAILPreprint
Giancotti, G., French, R., Hayward, O. A., Lee, K. Y., Robinson, T., da Silva, A. M. R., Varnava, A., MacFarlane, M., Clarkson, R. W. E., Westwell, A. D., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.22.590574
“However, such non-specific inhibitors have shown toxicity in phase I trials 14, 15 .”
BackgroundEpigenetic Alterations as an Adaptive Response to Chemotherapy
Rubiada, Fatima, K., Mushtaq, I., Kour, J., Wani, A., & Khan, S. U. (2024) · Springer eBooks · doi:10.1007/978-981-97-1666-1_7
Design, Synthesis, and Biological Evaluation of Indazole-Based Histone Deacetylase 6 InhibitorsPreprint
Ali, K. H., Gupta, S., Oh, Y. J., Hossain, M. M., Kim, J. H., Park, S. Y., & Seo, Y. H. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5178961
In vitro and in vivo activity of quisinostat against Toxoplasma gondii
Qiu, H.-J., Zheng, W.-B., Zeng, T., Yang, S., Liu, D.-A., Wang, L., Liu, Z., Zhu, X., & Zhou, C. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01819-24
“Quisinostat is a hydroxamate-based HDACi, demonstrating broad-spectrum antiproliferative activity against multiple cancer cells (19).”
Rizwan, A., Aqeel, A., Choudhary, F., Nizam, A., Khan, A., & Farooqi, H. (2025) · Nutrition · doi:10.1016/j.nut.2025.112955 · Cited by 2
Design, synthesis, and biological evaluation of phenylisoxazole-based histone deacetylase inhibitors
Qin, X., Han, M., Hu, P., Que, H., Shao, Z.-L., & Yan, D. (2025) · PLoS ONE · doi:10.1371/journal.pone.0334632
Joshi, A., Ratnapradipa, N., Hughes, J., Moore, E., Ekpenyong, A. E., & Shukla, S. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1695552 · Cited by 2
“…rationale behind using class-speci fi c or isoform speci fi c inhibitors instead of pan-inhibitors is to potentially reduce adverse effects like myelosuppression (reduced bone marrow activity) (46), cardiotoxicity (in terms of QT prolongation or ventricular arrythmia) (47), or immunosuppression (48).”
Mirahmadi, M., Hashemi, N., Tabatabaee, S. H., Shams, F., Teng, Y., & Rahimpour, A. (2026) · Biotech Studies · doi:10.38042/biotechstudies.1830114
“However, this nonselective inhibition contributes to a wide array of side effects, including gastrointestinal distress, thrombocytopenia, and cardiac toxicity, which limits their broader clinical use (Shah, 2019).”
YANG, Y. G., Ahmed, K. A. M., Dinislam, K., Prasad, P., & Atiya, A. (2026) · Journal of Chemistry · doi:10.1155/joch/4628759
Development of a new 18F-labeled PET tracer for potential application to HDAC2 neuroimaging
Huang, Y., Wang, Y., Wang, Y., Cheng, H., Siewko, A., Varela, B. L., Wang, C., & Xu, Y. (2026) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2026.109620
Mercuri, E. M., Byrne, B. J., Willis, T. A., Bourke, J. P., Bettica, P. U., Cazzaniga, S., Xue, H., & Darpö, B. (2026) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.70047
“10 A systematic review of 62 studies, including 3268 patients, found that QTc prolongation occurred in 4.4% of patients receiving HDAC inhibitor therapy for cancer.”
InfluentialRôle de l'histone désacétylase HDAC6 au cours de l'érythropoïèse humaine
Vong, P. (2022) · theses.fr (ABES) · doi:10.70675/699e8d9bz5404z43f6zabe7zdd0f0b6c8c42
Cancer Epigenomics in Precision Medicine
Esmaeilzadeh, A., Makoui, M. H., Ebrahimi, F., Taremi, S., Yeganeh, P. M., Afshari, F., Hadiloo, K., & Esmaeilzadeh, K. (2026) · Springer eBooks · doi:10.1007/978-981-95-6845-1_4
Fiorentino, F., Bontempi, G., Michetti, F., Pecci, V., Fabbrizi, E., Passeri, D., Corsetti, L., Farini, V., Casano, F., Gioiello, A., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02737
Shen, S. (2026) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2026.2676080
Liu, M., Xue, J., Xue, C., Qi, H., Tan, Y. L., Wang, X., & Gao, S. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c01013
Ishioka, H., Iwamura, Y., Konta, Y., Sato, K., Kato, K., Tanaka, T., Nakai, T., & Suzuki, N. (2026) · Life Sciences · doi:10.1016/j.lfs.2026.124599
Liu, K.-Y., Zhao, X., Liu, J., Li, M.-N., Cui, H., Wang, Z., & Zhou, X. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1951750
“Such off-target inhibition, together with altered acetylation of non-histone proteins, may disrupt normal physiological signaling, leading to adverse events such as arrhythmias and dysglycemia (Subramanian et al., 2010; Shah, 2019; Raouf and Moreno-Yruela, 2024; Abdallah, 2026).”
Xu, J., Zuo, Y., Zhang, T., He, Y., Long, T., Jiao, M., Lu, R., Xiong, K., & Chen, Y. (2025) · Advanced technology in neuroscience . · doi:10.4103/atn.atn-d-25-00022 · Cited by 1
Yang, X., Li, X., Huang, R., Zhou, Y., Li, H., Yao, P., Hu, Y., Liu, Y., Wang, C., & Bai, P. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c01054
Liao, H., Zhou, Y., Weng, X., Ren, D., Guo, W., Duan, C., Wang, M., & Luo, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1807015
BindingDB Entry 50019713: Discovery of (
BindingDB (2024) · UC San Diego · doi:10.7270/q24m98zb
BindingDB Entry 50013364: Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.
BindingDB (2022) · UC San Diego · doi:10.7270/q2f76h9k
BindingDB Entry 50020297: Discovery of (S)-N
BindingDB (2024) · UC San Diego · doi:10.7270/q2930zm3
Metadata
- Authors
- Shah, R. R.
- Corresponding author
- Shah, Rashmi R.
- ORCID
- Shah, Rashmi R.
- Venue
- Drug Safety
- Published
- 2019-01-16
- Volume
- 42
- Issue
- 2
- Pages
- 235-245
- ISSN
- 0114-5916 (ISSN-L)
- 1179-1942
- OpenAlex
- W2910383661
- Cited by
- 197
- References
- 69
- Citations by year
- 2026: 24 · 2025: 46 · 2024: 26 · 2023: 25 · 2022: 25 · 2021: 24 · 2020: 19 · 2019: 7
- FWCI
- 1.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Drug Safety (publishedVersion, public-domain)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- histone deacetylase inhibitors, tolerability, adverse drug reactions, myelosuppression, diarrhea, cardiotoxicity, QTc prolongation, atrial fibrillation, ventricular tachyarrhythmia, belinostat, chidamide, panobinostat, romidepsin, vorinostat, HDAC isoform selectivity, solid tumors, hematologic malignancies, T-cell lymphoma, multiple myeloma, combination therapy
- MeSH terms
- Animals, Antineoplastic Agents, Gastrointestinal Diseases, Histone Deacetylases, Humans, Hydroxamic Acids, Neoplasms, Sulfonamides, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.